MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy.

Purpose: To develop a novel MRI-based vector radiomic approach to predict breast cancer (BC) human epidermal growth factor receptor 2 (HER2) status (zero, low, and positive; task 1) and its changes after neoadjuvant therapy (NAT) (positive-to-positive, positive-to-negative, and positive-to-pathologic complete response; task 2).
Materials and Methods: Both dynamic contrast-enhanced (DCE) MRI data and multi-b-value (MBV) diffusion-weighted imaging (DWI) data were acquired in BC patients at two centers. Vector-radiomic and conventional-radiomic features were extracted from both DCE-MRI and MBV-DWI. After feature selection, the following models were built using the retained features and logistic regression: vector model, conventional model, and combined model that integrates the vector-radiomic and conventional-radiomic features. The models' performances were quantified by the area under the receiver-operating characteristic curve (AUC).
Results: The training/external test set (center 1/2) included 483/361 women. For task 1, the vector model (AUCs=0.73∼0.86) was superior to (p<.05) the conventional model (AUCs=0.68∼0.81), and the addition of vector-radiomic features to conventional-radiomic features yielded an incremental predictive value (AUCs=0.80∼0.90, p<.05). For task 2, the combined MBV-DWI model (AUCs=0.85∼0.89) performed better than (p<.05) the conventional MBV-DWI model (AUCs=0.73∼0.82). In addition, for the combined DCE-MRI model and the combined MBV-DWI model, the former (AUCs=0.85∼0.90) outperformed (p<.05) the latter (AUCs=0.80∼0.85) in task 1, whereas the latter (AUCs=0.85∼0.89) outperformed (p<.05) the former (AUCs=0.76∼0.81) in task 2. The above results are true for the training and external test sets.
Conclusions: MRI-based vector radiomics may predict BC HER2 status and its changes after NAT and provide significant incremental prediction over and above conventional radiomics.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)